In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to ...

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study Clinical trials frequently include multiple end points that ...

New date from the KEYNOTE-716 trial show distant metastasis-free survival benefit from pembrolizumab use in melanoma. The double-blind KEYNOTE-716 study (NCT03553836) is investigating the use of ...

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved pembrolizumab regimens for patients with PD-L1 positive, platinum-resistant ovarian cancers. A ...

Sarcomas, a diverse group of malignancies, exhibit substantial heterogeneity in both biological behavior and microenvironment, influencing their response to immunotherapy. Although pembrolizumab is ...

SAN FRANCISCO -- The use of adjuvant pembrolizumab (Keytruda) more than doubled disease-free survival (DFS) in high-risk muscle-invasive urothelial carcinoma (MIUC) after radical surgery, according to ...

CHICAGO — In patients with stage IVB anaplastic thyroid cancer, the inclusion of adjuvant pembrolizumab to conventional multimodal therapy shows significant benefits in reducing the recurrence risk ...

Highly anticipated overall survival results from the KEYNOTE-564 trial support the use of adjuvant pembrolizumab as a standard of care after nephrectomy for patients with clear cell RCC at increased ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...

Please provide your email address to receive an email when new articles are posted on . The patient received immunotherapy for squamous cell carcinoma. The patient was admitted for facial swelling ...